Clinical data | |
---|---|
Trade names | Zokinvy |
Other names | SCH 66336 |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | By mouth |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C27H31Br2ClN4O2 |
Molar mass | 638.83 g·mol−1 |
3D model (JSmol) | |
| |
|
Lonafarnib, sold under the brand name Zokinvy, is a medication used to treat Hutchinson-Gilford progeria syndrome and certain processing-deficient progeroid laminopathies.[1] It is used in people starting at a year old.[1] It is taken by mouth.[1]
Common side effects included nausea, headache, diarrhea, infection, muscle pain, electrolyte problems, weight loss, bone marrow suppression, liver inflammation, high blood pressure, and tiredness.[1] Other side effects may include kidney problems, vision problems, and decreased fertility.[1] Use during pregnancy may harm the baby.[1] It is a farnesyltransferase inhibitor.[1]
Lonafarnib was approved for medical use in the United States in 2020 and Europe in 2022.[1][2] In the United States, at the initial dose of 50 mg twice per day, it costs about 50,000 USD per month as of 2022.[3]
References
edit- ^ a b c d e f g h i j k "Lonafarnib capsule". DailyMed. Archived from the original on 22 January 2021. Retrieved 17 January 2021.
- ^ a b "Zokinvy EPAR". European Medicines Agency. 17 May 2022. Archived from the original on 2 August 2022. Retrieved 1 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Zokinvy Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 21 May 2022. Retrieved 3 November 2022.